The incidence of thrombocytopenia and anemia was low in these patients (16.2% and 11.6%, respectively) and the authors concluded that amrubicin is a tolerable treatment for this population despite the high incidence of neutropenia.[36] The authors also reported that growth factors (G-CSF) were administered as a prophylactic agent against leukopenia and neutropenia at the physician’s discretion.[36] However, the exact information about its use in the management of toxicities was not reported. The gene discussed is CSF3; the disease is neutropenia.